Abbott India News

Intimation under Regulation 30

Closure of Trading Window

Resignation Letter of Non-Executive Director.

Appointment of Additional Non-Executive Director

Resignation of Director

We refer to our earlier communication dated March 15, 2024, please find attached the resignation letter of Senior Management Personnel.

Communication to Shareholders : Intimation about Tax Deduction at Source on Dividend.

Newspaper Publication

State-run BPCL on Thursday posted a 35% drop in its standalone net profit at Rs 4,224 crore in the fourth quarter, compared with Rs 6,478 crore in the last year period.

Indian drugmaker Abbott India reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines.

Annual Secretarial Compliance Report for the year ended March 31, 2024

Record Date for Dividend

Annual General Meeting of the Company

RPT Statement

Board approves Final Dividend

Financial Results for the quarter and financial year ended March 31, 2024.

Outcome of Board Meeting

A close above Rs 26,600 which also coincides with the 20-week moving average could add more momentum to the stock pushing it toward the Rs 30,000 mark. Short-term traders with high-risk profiles can look to buy Abbott India on dips for a target above Rs 30,000 in the next 4-6 weeks, suggest experts.

Q4 results today: On Thursday, State Bank of India (SBI), the foremost public sector lender in India, will be among the 69 companies set to unveil their financial results for the quarter ending March 2024. Investors will also keep a close eye on companies like Asian Paints, BPCL, and Indian Overseas Bank as they announce their results.

ABBOTT INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2024 ,inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2024 and to recommend final dividend for the year ended March 31, 2024.

Voting Results and Scrutinizer''s Report for Postal Ballot.

Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Compliance Certificate under Reg 40 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Appointment of Senior Management Personnel

Compliance Certificate for the year ended March 31, 2024

Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018.

Intimation under Regulation 39(3) - Details of Loss of Certificate/Duplicate Certificate

Intimation under Regulation 30

Please find enclosed, copies of the advertisement published in Business Standard (All Editions in English) and Loksatta (in Marathi) today i.e., Wednesday, March 27, 2024, confirming the dispatch of Postal Ballot Notice through email, process for registration of email addresses and information for remote e-voting.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the Postal Ballot Notice dated March 13, 2024 along with the Explanatory Statement and e-voting instructions for seeking approval of the Members for the Ordinary Resolutions as set out in the Postal Ballot Notice by way of electronic voting. This is for your information and records.

Closure of Trading Window

Intimation under Regulation 30

We refer to our earlier communication dated December 19, 2023 regarding resignation of Managing Director. Further to the above communication, please find enclosed resignation letter of Managing Director for your information and records.

Resignation of Mr Sandeep Reddy - Commercial Director - Women''s Health, Metabolics and International Business as Senior Management Personnel of the Company effective June 5, 2024.

Appointment of Internal Auditors for the financial year 2024-25

The Board at its Meeting held today i.e., March 13, 2024 approved the appointment of Ms Swati Dalal (DIN: 01513751) as an Additional Director and the Managing Director of the Company with effect from April 1, 2024.

In the last three years, Novartis is the third MNC pharma company which has announced sale of a part of its business in India. Some of these restructuring are being done as part of the global readjustment being made at the parent companies level. The bigger question is whether after this restructuring will the MNC pharma stocks, which have been underperforming for quite some time, be able to make a comeback on the street or not. This answer to this question would depend on multiple factors. Right from the use of the sale proceeds to whether post restructuring focus would be on a 100 percent subsidiary or not. In both positive and negative cases, these stocks probably should be on watchlist as news flow around them increases in coming quarters. We take a look at 7 MNC pharma companies.

Intimation under Regulation 30

Newspaper Publication

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose a text of Unaudited Financial Results of the Company for the third quarter and nine months ended on December 31, 2023, approved by the Board of Directors at its Meeting held today i.e., Thursday, February 1, 2024 along with the Limited Review Report issued by S R B C & CO. LLP, Statutory Auditors of the Company. The Meeting of the Board of Directors of the Company commenced at 4.00 pm and concluded at 5.35 pm.